Bristol-Myers Squibb's acquisition of IFM Therapeutics was a strategic move aimed at bolstering its immunology and inflammation pipeline, harnessing innovative therapies to address unmet medical needs. To better understand the rationale behind this acquisition, leverage a pharma company-based actionable org chart. The sales intelligence tool will help to explore:

• Therapeutics alignment
• Research and development departments
• Key decision-makers post-acquisition
• Innovative therapies pipeline
• Strategic planning or alliances

You can view Org Charts HERE.